{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:13:38Z","timestamp":1783944818023,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016175","name":"Chulabhorn Royal Academy","doi-asserted-by":"publisher","award":["E2565\/033"],"award-info":[{"award-number":["E2565\/033"]}],"id":[{"id":"10.13039\/100016175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.anndiagpath.2026.152652","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:27:47Z","timestamp":1777580867000},"page":"152652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Determination of the optimal cell count for HER2 status assessment in fluorescence in situ hybridization"],"prefix":"10.1016","volume":"84","author":[{"given":"Kanthida","family":"Jangyubol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somboon","family":"Kittikongwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutamas","family":"Yimnoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongkod","family":"Petcharat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thivaratana","family":"Sinthuwiwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiyaphat","family":"Laohawetwanit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyavudh","family":"Herabutya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2026.152652_bb0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0010","series-title":"Global cancer observatory: cancer today","author":"Ferlay","year":"2018"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4132\/jptm.2019.11.03","article-title":"HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation","volume":"54","author":"Ahn","year":"2020","journal-title":"J Pathol Transl Med"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","article-title":"HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now","volume":"7","author":"Schlam","year":"2021","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12907-018-0081-4","article-title":"HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women","volume":"19","author":"Aman","year":"2019","journal-title":"BMC Clin Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ajcp\/aqz012","article-title":"Impact of the 2018 ASCO\/CAP HER2 guideline focused update","volume":"152","author":"Gordian-Arroyo","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0035","first-page":"40","article-title":"HER2-positive metastatic breast cancer: a comprehensive review","volume":"19","author":"Exman","year":"2021","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10555-022-10021-x","article-title":"Anti-HER2 therapy in metastatic breast cancer: many choices and future directions","volume":"41","author":"Wynn","year":"2022","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0045","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","article-title":"The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer","volume":"35","author":"Hsu","year":"2016","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111682","article-title":"Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan (DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985)","volume":"183","author":"Xu","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0055","article-title":"Impact of the 2018 ASCO\/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0060","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41392-019-0069-2","article-title":"Targeted therapeutic options and future perspectives for HER2-positive breast cancer","volume":"4","author":"Wang","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0065","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0070","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241775","article-title":"Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO\/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy","volume":"15","author":"Crespo","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0080","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ctrv.2013.09.001","article-title":"HER2 testing: current status and future directions","volume":"40","author":"Perez","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0085","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0090","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0095","doi-asserted-by":"crossref","first-page":"8231","DOI":"10.1038\/s41598-019-44643-z","article-title":"Automated detection of the HER2 gene amplification status in fluorescence in situ hybridization images for the diagnostics of cancer tissues","volume":"9","author":"Zakrzewski","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/his.13208","article-title":"Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough?","volume":"71","author":"Pol\u00f3nia","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/ajcp\/aqw017","article-title":"Optimal scoring of brightfield dual-color in situ hybridization for evaluation of HER2 amplification in breast carcinoma: how many cells are enough?","volume":"145","author":"Prendeville","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.anndiagpath.2026.152652_bb0110","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913426000481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913426000481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:50:07Z","timestamp":1783943407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913426000481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"alternative-id":["S1092913426000481"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2026.152652","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of the optimal cell count for HER2 status assessment in fluorescence in situ hybridization","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2026.152652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152652"}}